Trade iBio, Inc. - IBIO CFD

iBio, Inc. Company profile

iBio is a biopharmaceutical company behind the FastPharming System that helps with drug development “from concept to clinic”.

Headquartered in Texas, iBio was founded in 2008 and operates in biopharmaceuticals and bioprocessing segments along with its subsidiary, iBio CDMO LLC. 

iBio’s main product is the FastPharming System, which has helped produce monoclonal antibodies, subunit vaccines, cytokines and other recombinant proteins, according to the company’s site. 

iBio has also built the Glycaneering Development Services, which provides “greater control over the glycosylation of complex biopharmaceuticals''. 

The company operates in the fields of oncology, fibrotic and infectious diseases. 

The company’s development and manufacturing services deliver fast, scalable and sustainable solutions, enabling iBio to draw a licence agreement with Planet Biotechnology, and collaboration agreements with CC-Pharming Ltd, Safi BioSolutions and several other companies to develop therapeutic solutions.

The company went public in 2020 on the NYSE American. iBio, Inc. stock trades under the ticker symbol IBIO.

Check out the IBIO price history and today’s share value at Capital.com. Always stay on top of the latest price developments with our live IBIO stock chart.